ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial with Vafidemstat in Borderline Personality Disorder
MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, March 29th, 2021 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Borderline Personality Disorder | Clinical Trials | Pharmaceuticals | Spain Health | USA Health